# Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome

> **NCT01127503** · PHASE2 · TERMINATED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Velo-cardio-facial Syndrome
- Psychosis

## Interventions

- **DRUG:** Metyrosine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01127503
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2010-11
- **Final completion:** 2011-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Enrollment, study-design and execution challenges.
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01127503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01127503, "Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01127503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*